Caladrius Biosciences, Inc. (CLBS): Price and Financial Metrics
CLBS Price/Volume Stats
| Current price | $6.40 | 52-week high | $9.75 |
| Prev. close | $0.51 | 52-week low | $0.38 |
| Day low | $5.73 | Volume | 1,796,440 |
| Day high | $9.75 | Avg. volume | 522,308 |
| 50-day MA | $0.52 | Dividend yield | N/A |
| 200-day MA | $0.65 | Market Cap | 387.49M |
CLBS Stock Price Chart Interactive Chart >
Caladrius Biosciences, Inc. (CLBS) Company Bio
Caladrius Biosciences, Inc., formerly NeoStem, Inc., through its subsidiary, PCT, LLC, a Caladrius Company (PCT), provides development and manufacturing services to the cell therapy industry (which includes cell-based gene therapy). PCT specializes in cell and cell-based gene therapies.
Latest CLBS News From Around the Web
Below are the latest news stories about CALADRIUS BIOSCIENCES INC that investors may wish to consider to help them evaluate CLBS as an investment opportunity.
Life Sciences Virtual Investor Conference: Presentations Now Available for On-Demand ViewingNEW YORK, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the September Life Sciences Virtual Investor Conference are now available for on-demand viewing. REGISTER NOW OR LOGIN AT: https://bit.ly/3RSjiX2The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section. Companies are accep |
Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata TherapeuticsCompany to commence trading on The Nasdaq Capital Market under Ticker Symbol “LSTA” Lisata has approximately $76 million in cash and investments following transaction close Lisata strengthens Board of Directors and Executive Leadership Team, appointing seasoned biopharmaceutical and clinical development industry executives BASKING RIDGE, N.J. and SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius”) and Cend Therapeutics, Inc. (“Cend”) today annou |
Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata TherapeuticsAll Merger-related proposals approved at the Annual Meeting of StockholdersBASKING RIDGE, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), announced today that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of stockholders held September 13, 2022, its stockholders approved all of the merger-related proposals, including: (i) the Agreement and Plan of Merger and Reorganiz |
Life Sciences Virtual Investor Conference Agenda Announced for September 15thCompany Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Virtual Investor Conference to be held on September 15th. Individual investors, institutional investors, advisors, and analysts are invited to attend this virtual event showcasing live executive presentations from companies |
Caladrius Biosciences Announces Participation in Upcoming Investor Conferences in September 2022BASKING RIDGE, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today announced that David J. Mazzo, PhD, President and CEO of Caladrius, will participate in the following investor events: H.C. Wainwright 24th Annual Global Investment Conference (September 12-14, 2022)Location: Lotte New York Palace Hotel in New York C |
CLBS Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | -74.14% |
| 5-year | -86.10% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | 0.00% |
| 2021 | -41.15% |
| 2020 | -43.03% |
| 2019 | -29.49% |
Loading social stream, please wait...